Search

Your search keyword '"Jiang, Yuyong"' showing total 23 results
Start Over Author "Jiang, Yuyong" Publication Year Range Last 3 years
23 results on '"Jiang, Yuyong"'

4. THU-191 Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis

Author

Li, Minghui, primary, Cao, Weihua, additional, Jiang, Tingting, additional, Deng, Wen, additional, Wang, Shiyu, additional, Wu, Shuling, additional, Zhang, Lu, additional, Lu, Yao, additional, Chang, Min, additional, Liu, Ruyu, additional, Ding, Xiaoyan, additional, Shen, Ge, additional, Gao, Yuanjiao, additional, Hao, Hongxiao, additional, Chen, Xiaoxue, additional, Hu, Leiping, additional, Xu, Mengjiao, additional, Jiang, Yuyong, additional, Yi, Wei, additional, Xie, Yao, additional, and Song, Rui, additional

Published
2024
Full Text
View/download PDF

6. Development and Validation of a Machine Learning-Based Model Used for Predicting Hepatocellular Carcinoma Risk in Patients with Hepatitis B-Related Cirrhosis: A Retrospective Study.

Author

Hou, Yixin, Yan, Jianguo, Shi, Ke, Liu, Xiaoli, Gao, Fangyuan, Wu, Tong, Meng, Peipei, Zhang, Min, Jiang, Yuyong, and Wang, Xianbo

Subjects
ARTIFICIAL neural networks, DISEASE risk factors, HEPATOCELLULAR carcinoma, RECEIVER operating characteristic curves, CIRRHOSIS of the liver
Abstract

Objective was to estimate the 5-year cumulative risk of HCC in patients with HBC by utilizing an artificial neural network (ANN). Methods: We conducted this study with 1589 patients hospitalized at Beijing Ditan Hospital of Capital Medical University and People's Liberation Army Fifth Medical Center. The training cohort consisted of 913 subjects from Beijing Ditan Hospital of Capital Medical University, while the validation cohort comprised 676 subjects from People's Liberation Army Fifth Medical Center. Through univariate analysis, we identified factors that independently influenced the occurrence of HCC, which were then used to develop the ANN model. To evaluate the ANN model, we assessed its predictive accuracy, discriminative ability, and clinical net benefit using metrics such as the area under the receiver operating characteristic curve (AUC), concordance index (C-index), calibration curves. Results: In total, we included nine independent risk factors in the development of the ANN model. Remarkably, the AUC of the ANN model was 0.880, significantly outperforming the AUC values of other existing models including mPAGE-B (0.719) (95% CI 0.670– 0.768), PAGE-B (0. 710) (95% CI 0.660– 0.759), FIB-4 (0.693) (95% CI 0.640– 0.745), and Toronto hepatoma risk index (THRI) (0.705) (95% CI 0.654– 0.756) (p< 0.001 for all). The ANN model effectively stratified patients into low, medium, and high-risk groups based on their 5-year In the training cohort, the positive predictive value (PPV) for low-risk patients was 26.2% (95% CI 25.0– 27.4), and the negative predictive value (NPV) was 98.7% (95% CI 95.2– 99.7). For high-risk patients, the PPV was 54.7% (95% CI 48.6– 60.7), and the NPV was 91.6% (95% CI 89.4– 93.4). These findings were validated in the independent validation cohort. Conclusion: The ANNs model has good individualized prediction performance and may be helpful to evaluate the probability of the 5-year risk of HCC in patients with HBC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Utilizing machine learning-based predictive models to identify early virological recurrence in Chinese chronic hepatitis B patients following entecavir withdrawal

Author

Li, Xiaoke, primary, Qiu, Mei, additional, Huang, Yi, additional, Xiao, Huanming, additional, Chen, Hening, additional, Lu, Bingjiu, additional, Jiang, Yuyong, additional, Long, Fuli, additional, Lin, Hui, additional, He, Jinyu, additional, Zhang, Mingxiang, additional, Wu, Qikai, additional, Wang, Li, additional, Zhu, Xiaoning, additional, Gong, Man, additional, Sun, Jianguang, additional, Sun, Xuehua, additional, Sun, Fengxia, additional, Lu, Wei, additional, Xu, Weihua, additional, Du, Hongbo, additional, and Ye, Yong’an, additional

Published
2023
Full Text
View/download PDF

8. Consolidation treatment with Tiaogan-Buxu-Jiedu granule (Traditional Chinese Medicine compound) plus entecavir reduces virological relapse following entecavir withdrawal in Chinese patients with chronic hepatitis B: a randomized, controlled trial

Author

Li, Xiaoke, primary, Qiu, Mei, additional, Huang, Yi, additional, Xiao, Huanming, additional, Lu, Bingjiu, additional, Jiang, Yuyong, additional, Long, Fuli, additional, Lin, Hui, additional, Li, Shuo, additional, He, Jinyu, additional, Zhang, Mingxiang, additional, Wu, Qikai, additional, Wang, Li, additional, Zhu, Xiaoning, additional, Gong, Man, additional, Sun, Jianguang, additional, Sun, Xuehua, additional, Sun, Fengxia, additional, Lu, Wei, additional, Xu, Weihua, additional, Du, Hongbo, additional, and Ye, Yong’an, additional

Published
2023
Full Text
View/download PDF

10. Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection

Author

Zhang, Lu, primary, Jiang, Tingting, additional, Yang, Ying, additional, Deng, Wen, additional, Lu, Huihui, additional, Wang, Shiyu, additional, Liu, Ruyu, additional, Chang, Min, additional, Wu, Shuling, additional, Gao, Yuanjiao, additional, Hao, Hongxiao, additional, Shen, Ge, additional, Xu, Mengjiao, additional, Chen, Xiaoxue, additional, Hu, Leiping, additional, Yang, Liu, additional, Bi, Xiaoyue, additional, Lin, Yanjie, additional, Lu, Yao, additional, Jiang, Yuyong, additional, Li, Minghui, additional, and Xie, Yao, additional

Published
2023
Full Text
View/download PDF

11. Additional file 1 of Machine learning-based model for predicting the esophagogastric variceal bleeding risk in liver cirrhosis patients

Author

Hou, Yixin, Yu, Hao, Zhang, Qun, Yang, Yuying, Liu, Xiaoli, Wang, Xianbo, and Jiang, Yuyong

Abstract

Additional file 1: Supplementary Table 1. Demographic and clinical characteristics of patients. Supplementary Fig. 1. Calibration curves of EGVB incidences for 1 year in the training (A) and validation data sets (B) of the ANN model probabilities.

Published
2023
Full Text
View/download PDF

12. WED-138 - Utilizing machine learning-based predictive models to identify early virological recurrence in Chinese chronic hepatitis B patients following entecavir withdrawal

Author

Li, Xiaoke, Qiu, Mei, Huang, Yi, Xiao, Huanming, Chen, Hening, Lu, Bingjiu, Jiang, Yuyong, Long, Fuli, Lin, Hui, He, Jinyu, Zhang, Mingxiang, Wu, Qikai, Wang, Li, Zhu, Xiaoning, Gong, Man, Sun, Jianguang, Sun, Xuehua, Sun, Fengxia, Lu, Wei, Xu, Weihua, Du, Hongbo, and Ye, Yong’an

Published
2023
Full Text
View/download PDF

13. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B

Author

Li, Minghui, primary, Gao, Yuanjiao, additional, Yang, Liu, additional, Lin, Yanjie, additional, Deng, Wen, additional, Jiang, Tingting, additional, Bi, Xiaoyue, additional, Lu, Yao, additional, Zhang, Lu, additional, Shen, Ge, additional, Liu, Ruyu, additional, Wu, Shuling, additional, Chang, Min, additional, Xu, Mengjiao, additional, Hu, Leiping, additional, Song, Rui, additional, Jiang, Yuyong, additional, Yi, Wei, additional, and Xie, Yao, additional

Published
2022
Full Text
View/download PDF

16. Effect of decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消积方) plus chemoembolization on primary liver cancer in patients

Author

WU, Tong, YANG, Zhiyun, YANG, Yuying, JIANG, Yuyong, MENG, Peipei, LIU, Huimin, TIAN, Yehong, and ZHANG, Qiaoli

Subjects
Carcinoma, Hepatocellular, Treatment Outcome, Liver Neoplasms, Humans, Chemoembolization, Therapeutic, Combined Modality Therapy, Research Article, Drugs, Chinese Herbal
Abstract

OBJECTIVE: To investigate the effect of the decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消积方, FJXF) plus chemoembolization (TACE) on primary liver cancer (PLC) in patients, and study the underlying mechanism. METHODS: Patients with PLC who met the inclusion criteria were randomized into case group and control group. The case group was treated with FJXF combined with TACE. The control group was treated with TACE alone. The short-term clinical effect was evaluated; liver biochemistry, liver function index and multidrug resistance-associated indicators were detected. RESULTS: FJXF combined with TACE in the case group significantly increased the disease control rate than TACE alone in the control group (83.3% vs 61.1%). There was a reduction in the serum alpha-fetoprotein at 8 weeks after treatment in each group, while no difference between the two groups. The same trend can be observed for transaminase and direct bilirubin in both groups. In the case group, it showed a significant increase for albumin at 8 weeks after treatment, while no change in the control group. Multidrug resistance-associated indicators for multidrug resistance protein 1 and p-glycoprotein were upregulated in the case group but remained stable in the control group. CONCLUSIONS: FJXF combined TACE had a better short-term effect than TACE alone in patients with PLC. The potential mechanism was probably associated with alleviated multidrug resistance induced by FJXF. Additionally, FJXF didn’t increase the risk of liver damage in the combined therapy.

Published
2022

20. Integrating Chinese and western medicine for COVID‐19: A living evidence‐based guideline (version 1)

Author

Ge, Long, primary, Zhu, Hongfei, additional, Wang, Qi, additional, Li, Mengting, additional, Cai, Jianxiong, additional, Chen, Yang, additional, Chen, Yaolong, additional, Ding, Banghan, additional, Fang, Bangjiang, additional, Fei, Yutong, additional, Feng, Jihong, additional, Guo, Xinfeng, additional, Jiang, Rongmeng, additional, Jiang, Yuyong, additional, Li, Guiwei, additional, Li, Xiuhui, additional, Li, Xucheng, additional, Liang, Qun, additional, Liu, Jian, additional, Liu, Jianping, additional, Liu, Qingquan, additional, Liu, Shaonan, additional, Lu, Yun, additional, Miao, Qing, additional, Qi, Wensheng, additional, Shang, Hongcai, additional, Shi, Liqing, additional, Tan, XingHua, additional, Tang, Xudong, additional, Wang, Xianbo, additional, Wang, Xiaojun, additional, Xia, Wenguang, additional, Yang, Kehu, additional, Yang, Lihong, additional, Ye, Yongan, additional, Zhou, Qi, additional, Zhang, Hongchun, additional, Zhang, Junhua, additional, Zhang, Zhiming, additional, Zhang, Zhongde, additional, Zou, Xu, additional, Li, Jun, additional, and Wu, Darong, additional

Published
2021
Full Text
View/download PDF

22. SAT-179 - Consolidation treatment with Tiaogan-Buxu-Jiedu granule (Traditional Chinese Medicine compound) plus entecavir reduces virological relapse following entecavir withdrawal in Chinese patients with chronic hepatitis B: a randomized, controlled trial

Author

Li, Xiaoke, Qiu, Mei, Huang, Yi, Xiao, Huanming, Lu, Bingjiu, Jiang, Yuyong, Long, Fuli, Lin, Hui, Li, Shuo, He, Jinyu, Zhang, Mingxiang, Wu, Qikai, Wang, Li, Zhu, Xiaoning, Gong, Man, Sun, Jianguang, Sun, Xuehua, Sun, Fengxia, Lu, Wei, Xu, Weihua, Du, Hongbo, and Ye, Yong’an

Published
2023
Full Text
View/download PDF

23. Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-κB signaling pathway.

Author

Feng, Ying, Zhu, Bingbing, Liu, Yao, Zhou, Guiqin, Yang, Li, Liu, Long, Ren, Jie, Hou, Yixin, Yu, Hao, Meng, Peipei, Jiang, Yuyong, and Wang, Xianbo

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a pandemic that has caused a high number of deaths worldwide. Inflammatory factors may play important roles in COVID-19 progression. Yindan Jiedu granules (YDJDG) can inhibit the progression of COVID-19, but the associated mechanism is unclear.Purpose: To evaluate the therapeutic effects of YDJDG on COVID-19 and explore its underlying mechanism.Methods: We recruited 262 participants and randomly assigned 97 patients each to the YDJDG and control groups using one-to-one propensity score matching (PSM). Clinical effects were observed and serum inflammatory and immune indicators were measured. The target network model of YDJDG was established by predicting and determining the targets of identified compounds. The main constituents of the YDJDG extracts were identified and evaluated using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and molecular docking. Besides, the anti-inflammatory effects of YDJDG and its specific biological mechanism of action were studied.Results: After PSM, the results showed that compared with the control group, the YDJDG group had a shorter time of dissipation of acute pulmonary exudative lesions (p < 0.0001), shorter time to negative conversion of viral nucleic acid (p < 0.01), more rapid decrease in serum amyloid A level and erythrocyte sedimentation rate (p < 0.0001), and a higher rate of increase in CD4+T cell count (p = 0.0155). By overlapping the genes of YDJDG and COVID-19, 213 co-targeted genes were identified. Metascape enrichment analysis showed that 25 genes were significantly enriched in the NF-κB pathway, which were mainly targets of luteolin, quercetin, and kaempferol as confirmed by MS analysis. Molecular docking revealed that the ligands of three compounds had strong interaction with NF-κB p65 and IκBα. In vivo, YDJDG significantly protected animals from lipopolysaccharide (LPS)-induced acute lung injury (ALI), decreasing the lung wet/dry weight ratio, ALI score, and lung histological damage. In LPS-treated RAW264.7 cells, YDJDG suppressed nuclear translocation of NF-κB p65. In vivo and in vitro, YDJDG exerted anti-inflammatory effects by inhibiting the production of inflammatory cytokines (IL-6, IL-1β, and TNF-α). These effects were accompanied by the inhibition of NF-ĸB activation and IκBα phosphorylation.Conclusion: YDJDG may shorten the COVID-19 course and delay its progression by suppressing inflammation via targeting the NF-κB pathway. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results